Q4 2025 revenue was $9.2 million, a decrease of 26% from Q4 2024, but an increase of 20% from Q4 2024 Pro Forma. Full Year 2025 revenue was $38.7 million, a decrease of 18% from FY 2024, but an increase of 17% from FY 2024 Pro Forma. Q4 2025 income from continuing operations was $22.8 million, benefiting from a one-time, non-cash tax-related accounting adjustment. Full Year 2025 income from continuing operations was $25.0 million, benefiting from a one-time, non-cash tax-related accounting adjustment. Q4 2025 thyroid volume increased 11% year-over-year, and full year 2025 thyroid volume increased 13% year-over-year. Q4 2025 thyroid revenue increased 14% year-over-year, and full year 2025 thyroid revenue increased 21% year-over-year. The company completed its transition to a thyroid-only diagnostics testing company in 2025, discontinuing PancraGEN. Debt was fully paid off in Q4 2025, and cash availability increased by $4.3 million year-over-year.